Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk's Wegovy wins EU backing for reducing heart risks
Novo Nordisk's blockbuster Wegovy weight loss drug has received backing from the European Union's medical regulator to expand its use to include reducing the rise of serious heart events in overweight and obese adults. The Danish pharmaceutical giant said Thursday that the European Medical Agency had adopted a "positive opinion" on the label expansion, after reviewing the outcomes of a closely watched SELECT trial.
EU regulator backs use of Novo's Wegovy to lower heart risks
The European Medicines Agency has backed the use of Novo Nordisk's Wegovy to lower heart risks in overweight or obese adults, the company said on Thursday.
Wegovy approved in UK for cardiovascular problems in obese adults
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved semaglutide, known commercially as Wegovy, to reduce the risk of serious heart problems or strokes in overweight and obese adults. This approval makes semaglutide the first weight loss drug in the UK prescribed to prevent cardiovascular events in individuals with established cardiovascular disease.
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
In the most recent trading session, Novo Nordisk (NVO) closed at $133.28, indicating a +0.08% shift from the previous trading day.
Novo Nordisk's Wegovy weight loss drug wins UK approval for use as a heart treatment
The U.K.'s health regulator on Tuesday approved the use of Novo Nordisk's Wegovy weight loss drug to reduce the risk of overweight and obese adults suffering from serious heart problems or strokes. It follows similar label expansion by the U.S. Food and Drug Administration in March.
Novo Nordisk's Wegovy gets UK approval for lowering heart risks
Novo Nordisk's weight-loss drug Wegovy has secured the UK regulator's approval for its use to reduce the risk of overweight and obese adults suffering serious heart problems or strokes, the agency said on Tuesday.
Wegovy-maker Novo Nordisk buys land in Denmark for potential new production plant
Novo Nordisk , the maker of weight-loss drug Wegovy, has bought a site in Denmark's third largest city Odense and begun preparatory excavation works for a potential new production plant, it said on Tuesday,
Novo Nordisk Faces Setback in Netherlands Over Wegovy Insurance Coverage
The famed Danish drug maker Novo Nordisk A/S NVO expressed disappointment on Wednesday following a recommendation by the Dutch Health Care Institute advising the Netherlands government against including the company's popular weight-loss drug, Wegovy, in the basic insurance coverage.
Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note
In the most recent trading session, Novo Nordisk (NVO) closed at $140.87, indicating a -0.37% shift from the previous trading day.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novo Nordisk investor backs $100m Alzheimer's funding round
Novo Holdings, the main shareholder of Novo Nordisk (NYSE:NVO), has led a $100 million Series C funding round for Swiss company Asceneuron, which is developing a next-generation treatment for Alzheimer's. ASN51 is an oral small molecule drug targeting intracellular tau, protein tangles inside nerve cells, which could potentially revolutionize Alzheimer's treatment, according to Novo's senior partner Naveed Siddiqi.
Novo Nordisk (NVO) GLP-1 Drug Regarded Safe for Brain by Oxford
Oxford study demonstrates that Novo Nordisk's (NVO) semaglutide is not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications over one year.
